Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

No results yet

Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study

The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.

Citation:
Giannini F, Hogan AB, Cameron E, Le H, Minney-Smith C, Richmond P, Blyth CC, Glass K, Moore HC. Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study. Vaccine. 2025;56.

Keywords:
Compartmental model; Infant; Infectious disease modelling; Mathematical model; Nirsevimab; RSV; Respiratory syncytial virus; Transmission model

Abstract:
The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.